document.getElementById('index-articles-list').innerHTML = `

FDA approvals in 2024: new options for patients across cancer types and therapeutic classes

2024年FDA批准的新药：各类癌症和治疗分类患者的全新选择

Sundeep Agrawal,Esther Park,Paul G Kluetz

Nature reviews. Clinical oncology. 2025 Apr 11. DOI:10.1038/s41571-025-01018-w

HER2 testing: evolution and update for a companion diagnostic assay

HER2检测：伴随诊断产品的研发进展与更新要求

Charles J Robbins,Katherine M Bates,David L Rimm

Nature reviews. Clinical oncology. 2025 Apr 7. DOI:10.1038/s41571-025-01016-y

Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma

微小残留病态在多发性骨髓瘤临床管理中的机遇与挑战

Bruno Paiva,Qian Shi,Noemi Puig et al.

Nature reviews. Clinical oncology. 2025 Apr 7. DOI:10.1038/s41571-025-01017-x

Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers

MSI-H/dMMR肿瘤的流行病学、发病机制、生物学特性及日趋发展的治疗方法

Margherita Ambrosini,Paolo Manca,Vincenzo Nasca et al.

Nature reviews. Clinical oncology. 2025 Apr 3. DOI:10.1038/s41571-025-01015-z

Surrogate end points in oncology: the speed-uncertainty trade-off from the patients' perspective

肿瘤学中的替代终点指标：从患者的角度看待速度与不确定性之间的权衡

Vinay Prasad

Nature reviews. Clinical oncology. 2025 Mar 24. DOI:10.1038/s41571-025-01007-z

`; document.getElementById('index-articles-more').href = `https://i.iikx.com/journal/1759-4782.html`; document.getElementById('index-articles-more').innerHTML='更多内容'; document.getElementById('index-articles-more').style="float:right;background:var(--primary-color);color:#fff;font-size:13px;border-radius:5px;padding:0px 10px;margin-right:5px;line-height:1.7"; document.getElementsByClassName('index-artcles')[0].style.display = 'block'; document.getElementById('showJournalIndexUrl').style.display = 'block'; document.querySelector('#showJournalIndexUrl a').href = `https://i.iikx.com/journal/1759-4782.html`;